Breaking News Instant updates and real-time market news.

AMRN

Amarin

$18.06

0.39 (2.21%)

, LVS

Las Vegas Sands

$68.14

0.245 (0.36%)

07:35
04/22/19
04/22
07:35
04/22/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in Amarin (AMRN), Las Vegas Sands (LVS), Constellation Brands (STZ), Riot Blockchain (RIOT), StoneCo (STNE), McDermott (MDR), Zynga (ZNGA), Avaya Holdings (AVYA), Fitbit (FIT), and Honeywell (HON).

AMRN

Amarin

$18.06

0.39 (2.21%)

LVS

Las Vegas Sands

$68.14

0.245 (0.36%)

STZ

Constellation Brands

$198.83

7.2 (3.76%)

RIOT

Riot Blockchain

$5.39

0.57 (11.83%)

STNE

StoneCo

$26.50

-8.25 (-23.74%)

MDR

McDermott

$9.91

-0.58 (-5.53%)

ZNGA

Zynga

$5.43

0.175 (3.33%)

AVYA

Avaya

$19.02

0.04 (0.21%)

FIT

Fitbit

$5.38

-0.01 (-0.19%)

HON

Honeywell

$169.01

6.09 (3.74%)

  • 24

    Apr

  • 29

    Apr

  • 29

    Apr

  • 01

    May

  • 01

    May

  • 02

    May

  • 06

    May

  • 07

    May

  • 14

    May

  • 15

    May

  • 16

    May

  • 29

    May

  • 11

    Jun

  • 13

    Nov

AMRN Amarin
$18.06

0.39 (2.21%)

03/21/19
STFL
03/21/19
INITIATION
Target $27
STFL
Buy
Amarin initiated with a Buy at Stifel
Stifel analyst Derek Archila started Amarin with a Buy rating and $27 price target.
03/21/19
STFL
03/21/19
INITIATION
Target $27
STFL
Buy
Stifel starts Amarin with Buy rating, sees 'robust' growth for Vascepa
Stifel analyst Derek Archila initiated coverage of Amarin with a Buy rating and $27 price target. The shares closed the trading day down 25c to $18.76 but are trading up $1.08 to $19.84 in the after-hours market. Vascepa's Reduce-IT study results are "impressive" and a physician survey shows they will "most certainly lead to robust growth," likely above management's 2019 guidance, Archila tells investors in a research note. The analyst adds, though, that his call "runs counter to the prevailing sentiment" that Amarin will be acquired in the near term. He believes the outcome of an FDA advisory committee discussing the Reduce-IT results and controversies around them will be needed before a takeout can occur. Nonetheless, his due diligence with regulatory experts get him comfortable with an FDA approval for a Vascepa label expansion to include reduction in cardiovascular risk based on the Reduce-IT results in early 2020. This should effectively increase the drug's addressable market size by a factor of 20, says Archila. The analyst used a "blended methodology given the takeout premium in the stock" to arrive at a $27 target price.
03/28/19
JEFF
03/28/19
NO CHANGE
Target $30
JEFF
Buy
ADA addition should help drive Vascepa sales in 2019, says Jefferies
The American Diabetes Association updated its treatment guidelines to include Amarin's Vascepa for patients with diabetes and cardiovascular disease, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the addition as an incremental positive that should help drive Vascepa sales in 2019. Further, Q1 scripts suggest Vascepa sales of $80M-$85M, above the consensus estimate of $67M, Yee says. He keeps a Buy rating on Amarin with a $30 price target.
03/28/19
STFL
03/28/19
NO CHANGE
STFL
Buy
ADA endorsement a 'big score' for Amarin's Vascepa, says Stifel
After the American Diabetes Association updated its Standards of Medical Care to include a recommendation that Vascepa be considered for certain patients with diabetes, Stifel analyst Derek Archila called the news a "big score" for Vascepa and a significant endorsement of Vascepa's REDUCE-IT data. The analyst, who continues to view Amarin's 2019 Vascepa sales guidance as beatable, keeps a Buy rating on Amarin shares.
LVS Las Vegas Sands
$68.14

0.245 (0.36%)

04/18/19
STFL
04/18/19
NO CHANGE
Target $80
STFL
Buy
Las Vegas Sands price target raised to $80 from $72 at Stifel
Stifel analyst Steven Wieczynski raised his price target on Las Vegas Sands to $80 from $72, stating that the company "delivered another solid quarter" with "exceptional mass market gaming performance" in Macau and Singapore. However, while he expects shares to trade "modestly higher" following earnings, he does not see anything within the results or management's commentary capable of triggering a fundamental shift in the currently "decidedly mixed" sentiment on the stock. Wieczynski, who encourages investors to "look beyond the short-term noise," keeps a Buy rating on Las Vegas Sands shares.
04/18/19
DBAB
04/18/19
NO CHANGE
Target $69
DBAB
Hold
Las Vegas Sands price target raised to $69 from $60 at Deutsche Bank
Deutsche Bank analyst Carlo Santarelli raised his price target for Hold-rated Las Vegas Sands to $69 from $60 following the company's Q1 beat. The analyst views the report as "solid" but sees the stock's current valuation as "reasonable and fair."
04/18/19
JPMS
04/18/19
NO CHANGE
Target $71
JPMS
Neutral
Las Vegas Sands price target raised to $71 from $62 at JPMorgan
JPMorgan analyst Joseph Greff raised his price target for Las Vegas Sands (LVS) to $71 from $62 following the company's Q1 results. The analyst sees "lots of moving pieces" in the print and keeps a Neutral rating on the shares. Greff thinks there are reasons to be optimistic that the Macau market will rebound later in Q2 of Q3, but at current share levels, he sees more value and better risk/rewards in Wynn Resorts (WYNN) and Melco Resorts & Entertainment (MLCO).
04/17/19
HSBC
04/17/19
DOWNGRADE
Target $65.4
HSBC
Hold
HSBC downgrades Las Vegas Sands to Hold on valuation
HSBC analyst Charlene Liu downgraded Las Vegas Sands (LVS) to Hold from Buy and lowered her price target for the shares to $65.40 from $69.50. The analyst cites valuation for the downgrade and notes her new target implies 2% downside. Between Las Vegas Sands and Sands China (SCHYY), a stock Liu downgraded to Hold earlier this week, the analyst continues to prefer direct exposure to Macau through Las Vegas Sands' Hong Kong-listed subsidiary Sands China. She prefers Macau over Singapore for its "bigger market size and high growth potential." Liu maintains a Buy rating on Genting Singapore (GIGNY).
STZ Constellation Brands
$198.83

7.2 (3.76%)

04/05/19
BMOC
04/05/19
NO CHANGE
Target $225
BMOC
Outperform
Constellation Brands wine/spirit divestment reshapes portfolio, says BMO Capital
BMO Capital analyst Amit Sharma kept his Outperform rating and $225 price target on Constellation Brands after the company announced a divestment of lower priced wine and spirits brands, saying the move "re-shapes" its portfolio and positions it on a "clear path" to double-digit core earnings growth. The analyst adds that Constellation Brands's FY20 outlook is likely conservative and believes it can generate "continued multiple recovery" from current levels, with added benefits coming from its "free call option" on Canopy.
04/05/19
04/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Market Perform from Outperform at Wells Fargo with analyst Aaron Rakers saying the shares, after rallying 19% year-to-date, reflect a more balanced risk/reward. 2. Boston Beer (SAM) downgraded to Sell from Neutral at Goldman Sachs with analyst Judy Hong saying she sees headwinds in 2019 as competition intensifies and the company is "unlikely to repeat its innovation success again this year." 3. Ford (F) downgraded to Reduce from Neutral at Nomura Instinet with analyst Anindya Das saying Ford's higher share of the U.K. auto market compared to the rest of Europe makes it more susceptible to Brexit risks. 4. Constellation Brands (STZ) downgraded to Hold from Buy at Deutsche Bank. 5. International Paper (IP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Paul Quinn saying while International Paper is a "great company," investors have increased scrutiny on the containerboard market due to the "softening demand and fears of incremental capacity coming online" as year-to-date shipment growth slowed to 0.8% from 1.5% in 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/19
BOFA
04/05/19
NO CHANGE
Target $216
BOFA
Buy
Constellation Brands price target raised to $216 from $188 at BofA/Merrill
BofA Merrill Lynch analyst Bryan Spillane raised his price target on Constellation Brands shares to $216 after the company reported better than expected Q4 earnings, stating that he believes a premium valuation is warranted by the company's higher than average EPS growth and margin improvement prospects. Spillane keeps a Buy rating on Constellation shares.
04/05/19
MSCO
04/05/19
NO CHANGE
Target $230
MSCO
Overweight
Constellation Brands' FY20 guidance looks conservative, says Morgan Stanley
Morgan Stanley analyst Dara Mohsenian said he was surprised by the magnitude of the "relief rally" in Constellation Brands (STZ) shares following the company's Q4 report given that the company reported greater than expected near-term EPS dilution from its low-end wine sale, realized a lower than expected multiple on the wine transaction and unexpectedly did not provide forward guidance for Canopy Growth (CGC) equity losses. With that said, he sees "two clear positives" emerging from the quarter: the fact that fundamentals in the beer business remain solid and the fact that he sees solid visibility that Constellation can hit the high end of if $8.50-$8.80 FY20 EPS guidance, leaving aside Canopy equity losses. The analyst lowered his FY20 and FY21 EPS estimates to reflect dilution from the wine asset sale and trimmed his price target to $230 from $233, but he keeps an Overweight rating on Constellation shares.
RIOT Riot Blockchain
$5.39

0.57 (11.83%)

04/05/19
HCWC
04/05/19
NO CHANGE
Target $5
HCWC
Buy
Riot Blockchain price target raised to $5 from $4 at H.C. Wainwright
H.C. Wainwright analyst Kevin Dede raised his price target for Riot Blockchain to $5 from $4 and keeps a Buy rating on the shares. While the company's full-year filing implies Q4 mining slowed, the "ramifications are deemed irrelevant" by the recent bitcoin pricing trend, Dede tells investors in a research note. The analyst believes that while the Riot Blockchain share price still appears clearly driven by bitcoin pricing, the company represents "far more than a simplistic crypto mining operation."
10/04/18
HCWC
10/04/18
NO CHANGE
Target $4
HCWC
Buy
Riot Blockchain price target lowered to $4 from $10 at H.C. Wainwright
H.C. Wainwright analyst Kevin Dede lowered his price target for Riot Blockchain to $4 from $10 but keeps a Buy rating on the shares. The "ugly ramifications" of Riot's CEO departure in early September compounded by an increasingly difficult bitcoin mining and pricing environment have temporarily upended the company's fundamental development, Dede tells investors in a research note partially titled "Industry Dynamics Strain a Temporarily Fractured Business Model." The analyst, however, sees a "silver lining" in Riot's focus and commitment to building its cryptocurrency trading platform, RiotX. Dede remains bullish on bitcoin's "eventuality in fulfilling its utilitarian currency potential."
06/18/18
HCWC
06/18/18
NO CHANGE
Target $10
HCWC
Buy
Riot Blockchain risk of non-compliance eliminated, says H.C. Wainwright
H.C. Wainwright analyst Kevin Dede notes that Riot Blockchain on Friday completed its annual stockholders' meeting in full compliance with the SEC and in previous agreement with Nasdaq. In meeting filing requirements, there should be less controversy surrounding Riot's operation as a public company, Dede tells investors in a research note. Riot has now emerged apparently in full compliance with the supervisory bodies overseeing publicly traded companies, which presents a "compelling option in cryptocurrency investment," the analyst contends. He keeps a Buy rating on Riot Blockchain with a $10 price target.
06/12/18
HCWC
06/12/18
NO CHANGE
Target $10
HCWC
Buy
Riot Blockchain making good progress against plan, says H.C. Wainwright
H.C. Wainwright analyst Kevin Dede says Riot Blockchain's second successive monthly mining report illustrates good progress against its plan. Riot last week released its cryptocurrency mining production for the month of May that fell in line with expectations and was up 13% sequentially to 122 bitcoin from 100 bitcoin and 61 bitcoin cash in April, Dede tells investors in a research note. While still not yet available, the analyst believes Riot continues to make progress building its cryptocurrency trading platform. He expects a launch near term and keeps a Buy rating on the shares with a $10 price target.
STNE StoneCo
$26.50

-8.25 (-23.74%)

11/19/18
JPMS
11/19/18
INITIATION
Target $25
JPMS
Neutral
StoneCo initiated with a Neutral at JPMorgan
JPMorgan analyst Domingos Falavina started StoneCo with a Neutral rating and $25 price target. The analyst says his Neutral stance stems from the fact that his survey of 120 merchants show that they prioritize price over service or technology. The survey indicated that Stone was on average charging less than Cielo, says the analyst.
01/15/19
01/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. StoneCo (STNE) initiated with a Buy at BofA/Merrill. 2. Southwest Gas (SWX) initiated with a Market Perform at Wells Fargo. 3. Luna Innovations (LUNA) initiated with a Buy at B. Riley FBR. 4. Dell Technologies (DELL) initiated with a Neutral at UBS. 5. Elanco (ELAN) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/14/19
BOFA
01/14/19
INITIATION
Target $26
BOFA
Buy
StoneCo initiated with a Buy at BofA/Merrill
BofA/Merrill initiated StoneCo with a Buy and $26 price target.
04/05/19
SBSH
04/05/19
DOWNGRADE
SBSH
Neutral
StoneCo downgraded to Neutral from Buy at Citi
Citi analyst Felipe Gaspar Salomao downgraded StoneCo to Neutral from Buy.
MDR McDermott
$9.91

-0.58 (-5.53%)

04/23/18
SBSH
04/23/18
NO CHANGE
SBSH
McDermott bid would need to be closer to $10/share to break CB&I deal, says Citi
Citi said Subsea 7's hostile bid for McDermott (MDR) for $7 per share was an interesting and unexpected move, but the firm believes any proposal would have to be closer to $10 per share to disrupt the current terms of the deal with CB&I (CBI), which it notes is well down the road toward closing. Citi's "strong sense" is that McDermott, with the support of a majority of its board, is intent on staying the course in closing the deal with CB&I, adding that it thinks McDermott is buying CB&I at or near the bottom of a backlog cycle.
10/31/18
KEYB
10/31/18
DOWNGRADE
KEYB
Sector Weight
McDermott downgraded to Sector Weight from Overweight at KeyBanc
ZNGA Zynga
$5.43

0.175 (3.33%)

03/12/19
MSCO
03/12/19
NO CHANGE
Target $5.75
MSCO
Overweight
Zynga quarter-to-date bookings encouraging, says Morgan Stanley
Morgan Stanley analyst Brian Nowak said he thinks quarter-to-date trends for Zynga's portfolio imply modest organic growth in Q1 against record bookings last quarter, adding that he believes "Merge Dragons" is performing particularly well. After raising his 2019 and 2020 EBITDA estimates by 5% and 4%, respectively, driven by increased near-term expectations for "Merge Dragons" and "Empires & Puzzles," Nowak increased his price target on Zynga shares to $5.75 from $5.25 and keeps an Overweight rating on the stock.
03/26/19
MSCO
03/26/19
NO CHANGE
MSCO
Apple Arcade doesn't pose major threat to game makers, says Morgan Stanley
After Apple (AAPL) announced Arcade, a subscription service for mobile games, Morgan Stanley Brian Nowak said the service does not currently pose a major competitive threat to large game publishers Activision Blizzard (ATVI), Electronic Arts (EA) or Take-Two (TTWO). Apple's service doesn't include AAA quality content substitutable for their key franchises and didn't disclose plans to create its own first-party content, noted Nowak, who said that Apple could potentially be a direct competitor to mobile-focused Zynga (ZNGA). However, the overlap is limited by the fact that Zynga focuses exclusively on free-to-play, Nowak added.
04/22/19
PIPR
04/22/19
NO CHANGE
PIPR
Activision, Zynga Q1 mobile revenue have upside potential, says Piper Jaffray
Piper Jaffray analyst Michael Olson says his firm's Q1 "mobile meter" analysis of iOS app rankings suggests Q1 mobile revenue for Activision Blizzard (ATVI) and Zynga (ZNGA) has upside potential, with Glu Mobile (GLUU) likely in-line and Electronic Arts (EA) tracking slightly below. For Activision and Zynga, titles in the top 100 and average rank both improved quarter, Olson tells investors in a research note. For Activision, the analyst is modeling a 1% quarter-over-quarter decline in King revenue, while for Zynga, he's modeling a 26% increase in mobile. Glu Mobile rankings worsened quarter-over-quarter, as expected, due to seasonal decline in Tap Sports Baseball, says the analyst. However, he notes this appears in-line with his estimate for down 7% quarter-over-quarter in-app transaction revenue. EA mobile data was down quarter-over-quarter, Olson notes, but he estimates a 2% increase in mobile revenue, "so this is slightly below plan." The analyst keeps Overweight ratings on Activision, EA, Glu Mobile, Take-Two (TTWO) and Zynga.
02/07/19
PIPR
02/07/19
NO CHANGE
Target $6
PIPR
Overweight
Zynga price target raised to $6 from $5 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Zynga to $6 after the company reported Q4 bookings and adjusted EBITDA above consensus. Further, the company's Q1 bookings and adjusted EBITDA guidance also came in ahead of expectations, Olson tells investors in a post-earnings research note. The analyst believes Zynga's pipeline for 2019 may include a new Harry Potter title, Game of Thrones title, new expansion of the Merge! franchise, and either Farmville or Cityville mobile. He maintains an Overweight rating on the shares.
AVYA Avaya
$19.02

0.04 (0.21%)

01/25/19
LEHM
01/25/19
UPGRADE
Target $21
LEHM
Overweight
Barclays sees over 40% upside in Avaya shares, upgrades to Overweight
Barclays analyst Raimo Lenschow upgraded Avaya to Overweight from Equal Weight and raised his price target for the shares to $21 from $20. The analyst sees over 40% upside for the stock despite the company's status as a "legacy tech vendor." Since its return from bankruptcy in January 2018, Avaya has been largely ignored by equity investors and is trading at very low multiples, Lenschow tells investors in a research note. A return to legacy tech peer multiples alone could result in significant share price appreciation, says the analyst. He believes ongoing execution towards Avaya's fiscal 2019 revenue growth targets and better cash conversion will be positive catalysts.
03/11/19
GUGG
03/11/19
INITIATION
Target $22
GUGG
Buy
Avaya initiated with a Buy at Guggenheim
Guggenheim analyst Nandan Amladi started Avaya with a Buy rating and $22 price target. As a newly public company post-bankruptcy, Avaya has emerged with a "much stronger focus" on recurring revenue and an "aggressive" cloud roadmap targeting 25% of total revenue by fiscal 2021, from about 12% today, Amladi tells investors in a research note. He cites the company's combination of a "credible strategic pivot" and an "attractive valuation" for his Buy rating.
03/27/19
BWSF
03/27/19
NO CHANGE
Target $32
BWSF
Strong Buy
Avaya back on investor radars after buyout report, says BWS Financial
A report from Reuters about Avaya (AVYA) possibly being acquired by private equity has put the stock back on investors' radars, BWS Financial analyst Hamed Khorsand tells investors in a research note. He believes the "misunderstanding" of the company's business had "created a significant value gap." The analyst notes, however, that the news report suggests a takeover bid of $20, which is well below his price target of $32. The delta between the reported takeout price and the $32 target is predominately set on how much debt private equity would be willing to put back on Avaya's balance sheet, Khorsand contends. The analyst continues to believe there is "considerable possibility" of Avaya purchasing technology to fill-in its cloud offering. However, that should not prevent a going private bid, says Khorsand. He has a Buy rating on Avaya.
04/09/19
BWSF
04/09/19
NO CHANGE
Target $32
BWSF
Buy
Avaya could fetch up to $25 from PE buyer, says BWS Financial
Additional news reports about Avaya (AVYA) possibly going private since an initial Reuters report build some credibility about the news, said BWS Financial analyst Hamed Khorsand, who believes Avaya could fetch as much as $25 from a private equity buyer using fiscal 2019 estimates and could be worth as much $30 assuming no improvement in the business for fiscal 2020. He thinks greater synergies could be extracted by a strategic buyer and continues to believe Microsoft (MSFT) would be the best fit as an acquirer. Khorsand keeps a Buy rating and $32 price target on Avaya shares.
FIT Fitbit
$5.38

-0.01 (-0.19%)

02/28/19
DADA
02/28/19
UPGRADE
DADA
Buy
Fitbit upgraded to Buy from Neutral at DA Davidson
02/28/19
DADA
02/28/19
UPGRADE
Target $7
DADA
Buy
Fitbit upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Tom Forte upgraded Fitbit to Buy and raised his price target to $7 from $5.50 after its Q4 results and outlook for Q1 and FY19. The analyst attributes the upgrade to his view of "improvements that the management has made to the company's operating results, including a return to both unit and sales growth." Forte is also positive on Fitbit's "attractive balance sheet" and the progress made in its healthcare services efforts, saying the risk/reward on the stock is favorable given the after-market decline in the share price.
02/28/19
02/28/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Fitbit (FIT) upgraded to Buy from Neutral at DA Davidson analyst Tom Forte citing Q4 results and outlook for Q1 and FY19. 2. Hain Celestial (HAIN) upgraded to Overweight from Neutral at JPMorgan with analyst Ken Goldman citing the company's "compelling" investor day, the analyst has increased confidence in Hain's ability to drive margin growth over the next few years. 3. Athene Holding (ATH) upgraded to Outperform from Market Perform at BMO Capital with analyst James Fotheringham saying the valuation multiple on the stock may have finally passed its trough at its current 5.5-times two-year forward earnings multiple and believes that its core business should be valued at 6.4-times. 4. Wabco (WBC) upgraded to Neutral from Underweight at JPMorgan and to Hold from Sell at Vertical Research. 5. Globus Medical (GMED) upgraded to Buy from Neutral at UBS with analyst Matthew Taylor saying the company has delivered several quarters in a row of improving spine growth, which confirms robot placements are leading to implant pull-through. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/19
DADA
04/05/19
NO CHANGE
Target $7
DADA
Buy
Fitbit's Snap partnership a positive, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $7 price target on Fitbit (FIT) after it announced a Bitmoji partnership with Snap (SNAP) that allows users to access Bitmoji avatars on the face of their Fitbit smartwatches. The analyst says the deal is a positive for Fitbit as it seeks to increase customer engagement and "make personal health more fun".
HON Honeywell
$169.01

6.09 (3.74%)

04/22/19
DBAB
04/22/19
NO CHANGE
Target $187
DBAB
Buy
Honeywell price target raised to $187 from $174 at Deutsche Bank
Deutsche Bank analyst Nicole DeBlase raised her price target for Honeywell to $187 from $174 saying the company reported another "strong" quarter. The analyst believes Honeywell will be viewed as the best Q1 release in the space when all peers are done reporting. In a post-earnings research note titled "Simply The Best," DeBlase keeps a Buy rating on the shares.
03/25/19
DBAB
03/25/19
NO CHANGE
DBAB
Deutsche Bank makes 'Catalyst Call' to buy Honeywell, sell 3M
Deutsche Bank analyst Nicole DeBlase is making a "Catalyst Call" to buy shares of Honeywell (HON) and sell shares of 3M (MMM). The analyst sees continued potential for earnings beats and full year guidance raises from Honeywell given its "attractive exposure" to late-cycle end markets. These include, according to the analyst, aerospace and defense and non-residential construction, along with secular growth drivers such as warehouse automation. On the other hand, DeBlase forecasts a "substantial" 4% earnings miss in Q1 for 3M. The company is exposed to a number of end markets that have faced quarter-over-quarter deterioration, including automotive and electronics and China, the analyst tells investors in a research note. She does not view even the low end of 3M's guidance as achievable. Moreover, she points out that 3M is the most expensive stock she covers. DeBlase has a Buy rating on Honeywell with a Sell rating on 3M.
02/04/19
ARGS
02/04/19
NO CHANGE
Target $180
ARGS
Buy
Honeywell weakness offers buying opportunity, says Argus
Argus analyst John Eade kept his Buy rating and $180 price target on Honeywell, saying the stock's recent weakness offers a buying opportunity. The analyst notes the recent 10% slide from the highs in the shares because of tariff related concerns, but believes that the company can "generate low double-digit earnings growth over the next five years", benefiting from "diverse product lines as well as presence in the commercial aerospace and commercial construction markets." Eade adds that while China infrastructure growth is slowing, Honeywell's "mid-market" product sales in the country are growing.
02/04/19
DBAB
02/04/19
NO CHANGE
Target $160
DBAB
Buy
Honeywell price target raised to $160 from $153 at Deutsche Bank
Deutsche Bank analyst Nicole DeBlase raised her price target for Honeywell to $160 saying that despite high expectations, the company still delivered in Q4. Management sounded optimistic on the call, citing greater than 15% long-cycle backlog growth and no sign of slowdown in shortcycle markets outside of a few pockets of weakness, DeBlase tells investors in a post-earnings research note titled "A Bird In the Hand." The analyst keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

AGN

Allergan

$120.64

4.91 (4.24%)

06:50
06/19/19
06/19
06:50
06/19/19
06:50
Recommendations
Allergan analyst commentary  »

Allergan recent selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$18.73

-0.76 (-3.90%)

06:49
06/19/19
06/19
06:49
06/19/19
06:49
Syndicate
Kura Oncology 5.9M share Secondary priced at $17.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 20

    Jun

AZN

AstraZeneca

$40.94

0.96 (2.40%)

06:48
06/19/19
06/19
06:48
06/19/19
06:48
Hot Stocks
AstraZeneca announces Breztri Aerosphere approved in Japan for COPD »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

MRK

Merck

$84.49

1.19 (1.43%)

, AZN

AstraZeneca

$40.94

0.96 (2.40%)

06:48
06/19/19
06/19
06:48
06/19/19
06:48
Hot Stocks
AstraZeneca, Merck's LYNPARZA approved in Japan as maintenance treatment »

AstraZeneca (AZN) and…

MRK

Merck

$84.49

1.19 (1.43%)

AZN

AstraZeneca

$40.94

0.96 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 24

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 16

    Sep

  • 20

    Sep

SECO

Seeco Holding

$7.44

0.27 (3.77%)

06:48
06/19/19
06/19
06:48
06/19/19
06:48
Hot Stocks
Secoo Holding jointly establishes AI laboratory with CAS »

Secoo announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAUC

Diversified Restaurant

$0.75

-0.0275 (-3.53%)

06:47
06/19/19
06/19
06:47
06/19/19
06:47
Hot Stocks
Diversified Restaurant reports preliminary Q2 SSS up 7.2% »

Diversified Restaurant is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 25

    Sep

TPR

Tapestry

$30.30

0.64 (2.16%)

, ANF

Abercrombie & Fitch

$15.75

-0.295 (-1.84%)

06:46
06/19/19
06/19
06:46
06/19/19
06:46
Hot Stocks
Tapestry names Joanne Crevoiserat as CFO, effective August 1 »

Tapestry (TPR) announced…

TPR

Tapestry

$30.30

0.64 (2.16%)

ANF

Abercrombie & Fitch

$15.75

-0.295 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:45
06/19/19
06/19
06:45
06/19/19
06:45
General news
Breaking General news story  »

Week of 6/14 MBA Mortgage…

KIDS

OrthoPediatrics

$42.95

0.95 (2.26%)

06:42
06/19/19
06/19
06:42
06/19/19
06:42
Initiation
OrthoPediatrics initiated  »

OrthoPediatrics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAF

First American

$53.10

0.41 (0.78%)

06:40
06/19/19
06/19
06:40
06/19/19
06:40
Initiation
First American initiated  »

First American initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 13

    Nov

FNF

Fidelity National

$39.85

-0.035 (-0.09%)

06:40
06/19/19
06/19
06:40
06/19/19
06:40
Initiation
Fidelity National initiated  »

Fidelity National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

AUPH

Aurinia Pharmaceuticals

$6.37

0.03 (0.47%)

06:39
06/19/19
06/19
06:39
06/19/19
06:39
Hot Stocks
Aurinia Pharmaceuticals' director nominees recommended by ISS, Glass Lewis »

Aurinia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

06:39
06/19/19
06/19
06:39
06/19/19
06:39
Periodicals
Nissan, Renault ready to remedy corporate governance conflict, WSJ reports »

Nissan (NSANY) and…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FISV

Fiserv

$89.05

0.08 (0.09%)

, FDC

First Data

$26.50

-0.01 (-0.04%)

06:38
06/19/19
06/19
06:38
06/19/19
06:38
Initiation
Fiserv, First Data initiated  »

Fiserv initiated with an…

FISV

Fiserv

$89.05

0.08 (0.09%)

FDC

First Data

$26.50

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARMP

Armata Pharmaceuticals

$2.81

0.005 (0.18%)

06:36
06/19/19
06/19
06:36
06/19/19
06:36
Initiation
Armata Pharmaceuticals initiated  »

Armata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NCMI

National CineMedia

$6.44

-0.03 (-0.46%)

06:35
06/19/19
06/19
06:35
06/19/19
06:35
Upgrade
National CineMedia rating change  »

National CineMedia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

ARES

Ares Management

$27.30

-0.17 (-0.62%)

06:34
06/19/19
06/19
06:34
06/19/19
06:34
Hot Stocks
Ares Management-financed DCR subsidiary investing up to $165M in drilling JV »

A Development Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

APO

Apollo Global

$33.44

0.185 (0.56%)

, ARES

Ares Management

$27.30

-0.17 (-0.62%)

06:33
06/19/19
06/19
06:33
06/19/19
06:33
Hot Stocks
Chisholm Oil and Gas, Gastar Exploration announce strategic combination »

Chisholm Oil and Gas and…

APO

Apollo Global

$33.44

0.185 (0.56%)

ARES

Ares Management

$27.30

-0.17 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

ADBE

Adobe

$276.80

1.21 (0.44%)

06:30
06/19/19
06/19
06:30
06/19/19
06:30
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$77.18

-1.35 (-1.72%)

06:28
06/19/19
06/19
06:28
06/19/19
06:28
Conference/Events
Tyson Foods to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ENR

Energizer

$41.79

0.33 (0.80%)

, SPB

Spectrum Brands

$56.79

-0.94 (-1.63%)

06:28
06/19/19
06/19
06:28
06/19/19
06:28
Downgrade
Energizer, Spectrum Brands rating change  »

JPMorgan downgrades…

ENR

Energizer

$41.79

0.33 (0.80%)

SPB

Spectrum Brands

$56.79

-0.94 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 10

    Jul

MRK

Merck

$84.49

1.19 (1.43%)

06:27
06/19/19
06/19
06:27
06/19/19
06:27
Periodicals
Merck seeing small, midsize deals to expand cancer treatment portfolio, WSJ says »

Merck is seeking small…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 24

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 16

    Sep

  • 20

    Sep

AAPL

Apple

$198.52

4.62 (2.38%)

06:24
06/19/19
06/19
06:24
06/19/19
06:24
Periodicals
Apple explores moving 15%-30% of production capacity from China, Nikkei reports »

Apple has asked its major…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$84.49

1.19 (1.43%)

06:24
06/19/19
06/19
06:24
06/19/19
06:24
Conference/Events
Merck to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 24

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 16

    Sep

  • 20

    Sep

BA

Boeing

$374.21

19.31 (5.44%)

06:21
06/19/19
06/19
06:21
06/19/19
06:21
Periodicals
Concerns over pilots' strength delays 737 MAX return to flight, WSJ reports »

Plans to put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.